The Asian tiger mosquito (Aedes albopictus) is now established in 16 EU countries and 369 regions — three times more than a decade ago — and serves as a competent vector for dengue, chikungunya and Zika. ECDC recorded 81 chikungunya outbreaks and 1,124 local cases in Europe in 2025, including the first cluster in Alsace, and Italy's 2024 dengue season was the largest in European history. Health systems are not prepared: under the worst climate scenario, ECDC projects up to a fivefold rise in outbreaks by 2060. Existing countermeasures — larvicides, ovitraps, sterile-male releases, Wolbachia-modified males — only contain spread; the species, once established, cannot be eradicated by any single measure. Globally, Aedes-borne disease cost has been estimated at ~$95 billion, rising to ~$311 billion with medical sequelae. This paper describes the application of the ARBOK TRINITY architecture — a three-acid (HF/H₂SO₄/H₃PO₄ in patented ratios with water as the bulk phase) fine-mist solution originally validated on chitin-armored agricultural pests — to Aedes albopictus. The mechanism is physico-chemical disruption of the chitin–water interface on the insect cuticle and the surface microlayer of larval habitats, not neurotoxic kill. Treated zones become physiologically unsuitable; adults disperse within 6–8 hours and breeding activity ceases within 24 hours. Because the action is on physico-chemistry rather than a neuro-enzyme target, no resistance selection is expected. Residual acid is buffered by soil and water within hours, leaving no persistent residue. Application at 50 L/ha of working dilution; concentrate cost $1.6–2.6/L; per-hectare cost $80–130 vs. $150–300 for conventional adulticide chemistry. The intervention is positioned for entry-point interception at ports and tyre/plant import hubs, and for hot-spot suppression in yards, parks, storm drains and tyre depots.